Welcome to our dedicated page for Ensysce Biosciences news (Ticker: ENSC), a resource for investors and traders seeking the latest updates and insights on Ensysce Biosciences stock.
Ensysce Biosciences, Inc. reports developments as a clinical-stage pharmaceutical company focused on pain and central nervous system therapeutics designed to reduce opioid abuse and overdose risk. Its recurring updates center on the TAAP™ (Trypsin-Activated Abuse Protection) prodrug platform, the MPAR® (Multi-Pill Abuse Resistance) overdose-protection platform, and product candidates including PF614 and PF614-MPAR.
Company news also covers clinical-study progress, FDA-related designations and regulatory engagement, peer-reviewed data, scientific conference presentations, intellectual-property updates, financing transactions, financial results, Nasdaq compliance matters, board and governance changes, and strategic-review disclosures.
Ensysce Biosciences (NASDAQ:ENSC) reported Q1 2026 results and clinical progress. Cash was $0.7 million at March 31, 2026 versus $4.3 million at year-end 2025, with a subsequent $2.0 million convertible preferred financing tranche closed in April.
Q1 federal grants were $1.0 million (down from $1.3 million). R&D expenses rose to $3.3 million from $1.9 million, G&A declined to $1.2 million from $1.4 million, and net loss widened to $3.6 million from $1.9 million. Operationally, Ensysce reached 50% interim enrollment in its pivotal PF614-301 Phase 3 trial, secured IRB approval for PF614-MPAR-102 Part 3, published peer-reviewed MPAR clinical data, gained a European patent allowance for ADHD candidate PF8026, advanced OUD candidate PF9001 with HEAL and NIDA support, and its Board launched a formal review of strategic alternatives.
Ensysce Biosciences (NASDAQ: ENSC) announced a new Taiwan patent for its MPAR® (Multi-Pill Abuse Resistance) overdose protection technology, extending protection in that jurisdiction through 2042 and building on U.S. Patent No. 12,599,578 issued April 14, 2026.
MPAR®, which has FDA Breakthrough Therapy designation, is designed to reduce opioid impact during overdose. In clinical studies, PF614-MPAR provided pain relief when used as directed while limiting excessive opioid release with multiple doses. The platform is also being applied to amphetamines and methadone, and National Institute on Drug Abuse funding supports ongoing clinical trials.
Ensysce Biosciences (NASDAQ:ENSC) CEO Dr. Lynn Kirkpatrick presented at the Pain Therapeutics Summit Europe in Amsterdam on May 7-8, 2026. Her May 7 talk, "Chemical Control, Clinical Confidence: Rethinking Opioids," described molecularly engineered opioid approaches and highlighted Ensysce platforms TAAP14 and MPAR AE aimed at reducing misuse and overdose risk. She also joined a panel on developing safer analgesics without sacrificing efficacy.
Ensysce Biosciences (NASDAQ:ENSC) received IRB approval to start Part 3, the final stage, of the PF614-MPAR-102 clinical study evaluating its MPAR® overdose-protection technology.
PF614-MPAR, which holds FDA Breakthrough Therapy designation and has NIDA-supported research funding, is engineered to limit additional opioid release during supratherapeutic oral dosing while preserving therapeutic exposure.
Ensysce Biosciences (NASDAQ:ENSC) closed a second tranche of convertible preferred financing of $2.0 million on April 7, 2026, under a prior commitment providing up to $20 million over 24 months. The tranche has a $0.55 fixed conversion price and alternate conversion tied to average common prices.
The financing carries 100% warrant coverage with an 18-month term and an additional 100% warrant coverage with a five-year term, each exercisable at the fixed conversion price subject to adjustment. Proceeds will fund flagship abuse- and overdose-resistant analgesic programs and general corporate needs, alongside federal grant support for the MPAR program.
Ensysce Biosciences (NASDAQ:ENSC) reported 2025 operational progress and year-end financials on March 30, 2026. Key clinical milestones include initiation of the PF614 Phase 3 (PF614-301) trial and continued development of PF614-MPAR under Breakthrough Therapy designation. The company received FDA feedback supporting overdose-protection labeling and a streamlined 505(b)(2) pathway.
Financials: cash $4.3M, federal grant funding $5.1M for 2025, R&D $10.4M (up $3.2M YoY), and net loss $10.2M for 2025. U.S. patent allowance extends MPAR protection through 2042.
Ensysce Biosciences (NASDAQ:ENSC) initiated a live "Ask Me Anything" (AMA) session on March 4, 2026 to discuss strategic execution, regulatory risk mitigation, and pipeline prioritization for PF614.
The AMA featured CEO Dr. Lynn Kirkpatrick addressing Phase 3 sequencing, capital discipline, commercial potential for PF614, and next steps; a replay is available on the company website.
Ensysce Biosciences (NASDAQ:ENSC) announced the peer-reviewed publication of Phase 1 clinical data for PF614-MPAR, an oxycodone prodrug using MPAR® technology that limits oral overdose while preserving therapeutic opioid exposure.
Findings show appropriate plasma levels at normal dosing and prevention of large opioid increases at supratherapeutic doses; MPAR received FDA Breakthrough designation in January 2024 and IP extends through 2042.
Ensysce Biosciences (NASDAQ:ENSC) announced on February 25, 2026 that its Board has launched a formal review of strategic alternatives to enhance shareholder value. The review may include partnerships, licensing, capital formation, business combinations, asset sales, or other corporate transactions.
The company said there is no timetable and no assurance a transaction will result; further disclosure will occur only if the Board approves a transaction or is required by law. Leadership emphasized continued focus on advancing TAAP™ and MPAR® platforms.
Ensysce Biosciences (NASDAQ:ENSC) announced executive presentations at four scientific and industry events in March–June 2026, highlighting its PF614 and PF614-MPAR programs and TAAP/MPAR platforms. Company executives will discuss emerging clinical data, development strategy, abuse-reduction approaches, and commercial launch best practices.
Key dates: USASP Mar 23-26, 2026; European Pain Summit May 7-8, 2026; Commercial Excellence Lab Jun 3-4, 2026; CPDD Jun 13-17, 2026.